Research Paper Volume 12, Issue 22 pp 22550—22563

The therapeutic value of XL388 in human glioma cells

Figure 5. XL388 oral administration inhibits A172 xenograft growth in SCID mice. The SCID mice bearing A172 xenografts (n=10 per group) were administrated with vehicle (saline, “Veh”) or XL388(5 mg/kg body weight, daily, × 14d), then tumor volumes (in mm3) (A) and mice body weights (in grams) (D) was recorded every seven days for a total of 35 days; The estimated daily tumor growth (in mm3 per day) was calculated as described (B). At treatment Day-35, all tumors were isolated and individually weighted (C). At treatment Day-7, two hours after initial XL388administration, the xenograft tumors were isolated. Tissue lysates were subjected to Western blotting assays of listed proteins (E and F). *p < 0.05 vs. “Veh” group (AC).